Prescription omega-3 fatty acid products and dietary supplements are not interchangeable

Managed Care

Volumn 2016, Issue JAN, 2016, Pages

  Hilleman, Daniel E ^a   Smer, Aiman ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Dietary supplements; Docosahexaenoic acid; Eicosapentaenoic acid; Hypertriglyceridemia; Icosapent ethyl; Omega 3 fatty acids

Indexed keywords

EID: 84974812289     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (83)

1. ACS (American Cancer Society). Dietary supplements: what is safe? http://m.cancer.org/acs/groups/cid/documents/webcontent/002385-pdf.pdf. Accessed Dec. 15, 2015.
2. ADA (American Diabetes Association). Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1): S1-S93.
3. Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
4. Ando K, Watanabe T, Daidoji H, et al. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract 12007]. Circulation. 2015;132:A12007.
5. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83(6 suppl):1467S-1476S.
6. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984-992.
7. Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37-46.
8. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;10(5)8:682-690.
9. Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr. 2012;142(1):99-104.
10. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-366.
11. Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. P T. 2013;38(11):681-691.
12. Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev. 2004;9(4):420-428.
13. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.
14. Casula M, Soranna D, Catapano AL, Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14(2):243-251.
15. Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252-259.
16. Cohen PA. Hazards of hindsight-monitoring the safety of nutritional supplements. N Engl J Med. 2014;370(14):1277-1280.
17. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr. 2000;71(1 suppl):171S-175S.
18. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354-1367.
19. Dawson K, Zhao L, Adkins Y, et al. Modulation of blood cell gene expression by DHA supplementation in hypertriglyceridemic men. J Nutr Biochem. 2012;23(6):616-621.
20. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-455.
21. Domei T, Amemiya K, Enomoto S, et al. Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy [abstract P689]. Eur Heart J. 2013;34(suppl 1):137.
22. Epanova (omega-3-carboxylic acids) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2014.
23. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014;8(1):29-60.
24. FDA (US Food and Drug Administration), Center for Drug Evaluation and Research. Omtryg Medical Reviews. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204977Orig1s000MedR.pdf. Accessed Dec. 15, 2015.
25. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 2015. http://www.accessdata.fda.gov/scripts/cder/ob. Accessed Dec. 15, 2015.
26. FDA. Regulatory information: Dietary supplement health and education act of 1994. Last update: 2009. http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/ucm148003.htm. Accessed Dec. 15, 2015.
27. Gajos G, Rostoff P, Undas A, et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55(16):1671-1678.
28. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
29. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-1230.
30. Glaxo Smith Kline. Patient assistance programs. http://www.gskforyou.com/patient-assistance-programs/drugslist.html. Accessed Dec. 15, 2015.
31. Gurbel PA, Bliden K, Franzese C, et al. Disconnect between reported fish oil capsule intake and plasma omega-3 fatty acid levels [abstract]. J Am Coll Cardiol. 2015;65:A1632.
32. Halvorsen BL, Blomhoff R. Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements. Food Nutr Res. 2011;55:5792.
33. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385-391.
34. Hawkins EB, Ling H, Burns TL, et al. Perceptions, knowledge, and patterns of use of "fish oil" products in cardiac patients [abstract 23]. Pharmacotherapy. 2012;32:e184.
35. Ishida T, Ohta M, Nakakuki M, et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: Participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids. 2013;88(4):281-288.
36. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5-18.
37. Jarcho JA, Keaney JF Jr. Proof that lower is better-LDL cholesterol and IMPROVE-IT. N Engl J Med. 2015;372(25):2448-2450.
38. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
39. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53(12):2525-2545.
40. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94-108.
41. Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric. 2015;95:1260-1267.
42. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015-2026.
43. Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and Blue Cross of Idaho. LipidSpin. 2010;8:32-34.
44. Lovaza (omega-3-acid ethyl esters) [package insert; prior to removal of efficacy data in patients with high triglycerides]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
45. Lovaza (omega-3-acid ethyl esters) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.
46. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400-1411.
47. Mason RP, Jacob R, Beauregard G, et al. Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]. J Clin Lipidol. 2011;5:201.
48. Mason RP, Jacob RF, Corbalan JJ, et al. Combination eicosapentaenoic acid and statin treatment reversed endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract 160]. J Clin Lipidol. 2014;8:342-343.
49. Mason R, Sherratt S. Analysis of omega-3 fatty acid dietary supplements with respect to content: are they appropriate for patients? [abstract E21]. J Manag Care Spec Pharm. 2015;21:S34.
50. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-2067.
51. Niaspan (niacin extended-release) [package insert]. North Chicago, IL: AbbVie; 2015.
52. Nieman K, Dicklin M, Bell M, et al. Relationship between baseline triglyceride concentration and triglyceride reduction with 4 g/d long-chain omega-3 acid ethyl esters [abstract 1035.6]. FASEB J. 2014;28:1035.6.
53. Niki T, Wakatsuki T, Bando M, et al. Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems [abstract 14434]. Circulation. 2012;126:14434.
54. Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114-119.
55. Nomura S, Shouzu A, Omoto S, et al. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Thromb. 2009;16(2):83-90.
56. Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2009;206(2):535-539.
57. Omtryg (omega-3-acid ethyl esters A) [package insert]. Arlington, VA: Trygg Pharma; 2014.
58. Opperman M. What health professionals should know about omega-3 fatty acid supplements. S Afr J Clin Nutr. 2013;26(2):6-11.
59. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.
60. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143(2):285-297.
61. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152-2159.
62. Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800-1808.
63. Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric. 2013;93(8):1935-1939.
64. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.
65. Rupp H, Rupp KG. Adverse effects of ethyl esters or oxidation products in omega-3 preparations? Cardiovasc J Afr. 2014;25(2):86-87.
66. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450-458.
67. Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59(4):297-304.
68. Schmier JK, Hulme-Lowe C, Nelson JR, et al. A novel cost effectiveness model of eicosapentaenoic acid (EPA) for secondary prevention in the United States [abstract 243]. Circ Cardiovasc Qual Outcomes. 2015;8:A243.
69. Shim SM, Santerre CR, Burgess JR, Deardorff DC. Omega-3 fatty acids and total polychlorinated biphenyls in 26 dietary supplements. J Food Sci. 2003;68(8):2436-2440.
70. TG and HDL Working Group of the Exome Sequencing Project NHLaBI. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22-31.
71. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361(9356):477-485.
72. Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28(1):53-59.
73. Trilipix (fenofibric acid) [package insert]. North Chicago, IL: AbbVie; 2015.
74. Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract P72]. Circulation. 2007;115:e238.
75. Uehara H, Miyagi N, Shimajiri M, et al. The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495]. Eur Heart J. 2013;34(suppl 1):1011.
76. Vascepa (icosapent ethyl) [package insert]. Bedminster, NJ: Amarin Pharma; 2015.
77. Vascepa web site. Vascepa (icosapent ethyl) savings card program. Amarin Pharma Inc. https://vascepasavings.com/patient.php. Accessed Dec. 15, 2015.
78. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13(6):474-483.
79. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230(2):381-389.
80. Weitz D, Weintraub H, Fisher E, et al. Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010;18(5):258-263.
81. Yamano T, Kubo T, Shiono Y, et al. Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J Atheroscler Thromb. 2015;22(1):52-61.
82. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098.
83. Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord. 2011;9(4):255-271.